Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs Capmatinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 13 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
- 13 Jan 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.